Best Stocks Under $10.00 for 2018

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $10.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $10.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Aratana Therapeutics (NASDAQ:PETX)

Stock Price: $5.36
Market Cap: $255.52 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.40 (56.7% Upside)

Aratana Therapeutics logoAratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
#2 - Conatus Pharmaceuticals (NASDAQ:CNAT)

Stock Price: $4.77
Market Cap: $143.79 million
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $11.7980 (147.3% Upside)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.
#3 - MEI Pharma (NASDAQ:MEIP)

Stock Price: $3.75
Market Cap: $266.68 million
P/E Ratio: -5.1
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.10 (116.0% Upside)

MEI Pharma logoMEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
#4 - Genocea Biosciences (NASDAQ:GNCA)

Stock Price: $0.72
Market Cap: $62.72 million
P/E Ratio: -0.4
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.20 (480.1% Upside)

Genocea Biosciences logoGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
#5 - Recro Pharma (NASDAQ:REPH)

Stock Price: $7.23
Market Cap: $149.79 million
P/E Ratio: -3.6
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $13.60 (88.1% Upside)

Recro Pharma logoRecro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
#6 - Iovance Biotherapeutics (NASDAQ:IOVA)

Stock Price: $9.89
Market Cap: $945.40 million
P/E Ratio: -7.0
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.4375 (147.1% Upside)

Iovance Biotherapeutics logoIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
#7 - ADMA Biologics (NASDAQ:ADMA)

Stock Price: $5.53
Market Cap: $256.31 million
P/E Ratio: -2.9
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.50 (89.9% Upside)

ADMA Biologics logoADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
#8 - SCYNEXIS (NASDAQ:SCYX)

Stock Price: $1.03
Market Cap: $48.42 million
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.3750 (421.8% Upside)

SCYNEXIS logoSCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
#9 - Resonant (NASDAQ:RESN)

Stock Price: $3.34
Market Cap: $90.12 million
P/E Ratio: -2.7
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.20 (145.5% Upside)

Resonant logoResonant Inc., a late-stage development company, engages in the development of filter designs for radio frequency (RF) front-ends used in the mobile device industry in the United States. It uses Infinite Synthesized Networks technology to configure and connect resonators, the building blocks of RF filters. The company develops a series of single-band designs for frequency bands; and multiplexer filter designs for two or more bands to address the carrier aggregation, as well as filter designs to replace various filters and associated componentry for various bands. Resonant Inc. was founded in 2012 and is headquartered in Goleta, California.
#10 - Ardelyx (NASDAQ:ARDX)

Stock Price: $3.89
Market Cap: $241.39 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $11.8333 (204.2% Upside)

Ardelyx logoArdelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
#11 - Ocular Therapeutix (NASDAQ:OCUL)

Stock Price: $6.17
Market Cap: $238.11 million
P/E Ratio: -2.8
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $13.25 (114.7% Upside)

Ocular Therapeutix logoOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
#12 - Marinus Pharmaceuticals (NASDAQ:MRNS)

Stock Price: $5.72
Market Cap: $231.80 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $19.6667 (243.8% Upside)

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
#13 - Akoustis Technologies (NASDAQ:AKTS)

Stock Price: $4.12
Market Cap: $91.85 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.0833 (193.3% Upside)

Akoustis Technologies logoAkoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industries in the United States. The company operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and smart systems technology and commercialization center foundry, as well as manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, and Wi-Fi premise equipment. Akoustis Technologies, Inc. is headquartered in Huntersville, North Carolina.
#14 - Nabriva Therapeutics (NASDAQ:NBRV)

Stock Price: $2.66
Market Cap: $1.77 billion
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $13.40 (403.8% Upside)

Nabriva Therapeutics logoNabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
#15 - Synlogic (NASDAQ:SYBX)

Stock Price: $9.04
Market Cap: $229.90 million
P/E Ratio: -1.5
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $19.80 (119.0% Upside)

Synlogic logoSynlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
#16 - Adesto Technologies (NASDAQ:IOTS)

Stock Price: $4.24
Market Cap: $124.10 million
P/E Ratio: -17.7
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.00 (135.8% Upside)

Adesto Technologies logoAdesto Technologies Corporation, together with its subsidiaries, provides application-specific semiconductors for the Internet of Things (IoT) era. Its portfolio of semiconductor and embedded technologies are optimized for connected IoT devices used in industrial, consumer, communications, and medical applications. The company manufactures its products using industry-standard floating gate technology and conductive bridging random access memory technology platforms. Its products include DataFlash for data-logging applications, such as industrial automation, home automation sensing, and health and fitness tracking; Fusion Serial Flash for use in various high-volume consumer applications comprising wearables, mobile, and other applications; EcoXip that enables improved processor performance and reduced system power consumption; and Standard Serial Flash to store boot or program code with a low pin count industry standard serial interface. The company's products also comprise Mavriq for IoT and other applications, which include camera sensors, Bluetooth low energy devices, wearables, gaming components, printer cartridges, medical equipment, and other devices; and Moneta for retail beacons, wearable medical and fitness devices, industrial and environmental sensors, agricultural monitors, and other low energy/long battery life or energy harvesting system applications. The company sells its products through a network of representatives and distributors to original equipment manufacturers and original design manufacturers in the United States, Rest of Americas, Europe, the Asia Pacific, and internationally. Adesto Technologies Corporation was incorporated in 2006 and is headquartered in Santa Clara, California.
#17 - Lonestar Resources US (NASDAQ:LONE)

Stock Price: $8.89
Market Cap: $219.02 million
P/E Ratio: -21.2
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $11.50 (29.4% Upside)

Lonestar Resources US logoLonestar Resources US Inc., an independent oil and gas company, engages in the acquisition, development, and production of unconventional oil, natural gas liquids, and natural gas properties in the United States. The company primarily focuses on Eagle Ford Shale properties in Texas counties. Lonestar Resources US Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
#18 - Viewray (NASDAQ:VRAY)

Stock Price: $9.50
Market Cap: $714.47 million
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.7857 (34.6% Upside)

Viewray logoViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
#19 - Scorpio Tankers (NYSE:STNG)

Stock Price: $1.74
Market Cap: $580.69 million
P/E Ratio: -3.7
Dividend Yield: 2.30 %
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.0250 (131.3% Upside)

Scorpio Tankers logoScorpio Tankers Inc., together with its subsidiaries, engages in the seaborne transportation of refined petroleum products worldwide. As of March 22, 2018, its fleet consisted of 109 tankers, including 38 LR2, 12 LR1, 45 MR, and 14 Handymax tankers with an average age of approximately 2.6 years; and 20 time or bareboat chartered-in tankers, which include 2 LR2, 10 MR, and 8 Handymax tankers. The company was founded in 2009 and is based in Monaco.
#20 - Clearside Biomedical (NASDAQ:CLSD)

Stock Price: $5.48
Market Cap: $175.49 million
P/E Ratio: -2.4
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $22.40 (308.8% Upside)

Clearside Biomedical logoClearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel